Protara Therapeutics (TARA) said Thursday that its investigational therapy TARA-002 demonstrated a complete response rate of 72% at six months in a phase 2 trial involving patients with non-muscle invasive bladder cancer.

The company said the complete response rate across Bacillus Calmette-Guerin exposures reached 70% at any time, with 100% of patients maintaining complete response and two of three patients sustaining response at nine months.

Protara said it expects international site expansion to accelerate enrollment and plans to share initial data from 12 months in mid-2025.

The investigational drug showed a favorable safety and tolerability profile, with no grade 2 or greater treatment-related adverse events, the company added.

Shares of the company surged more than 128% in recent premarket activity.